FDA eases hold as Marker Therapeutics T-cell manufacturing issues addressed 

11th February 2020 Uncategorised 0

Marker Therapeutics says it has overcome an issue in its MultiTAA-specific T cell manufacturing process that led the FDA to stymie its trial in patients with acute myeloid leukemia (AML) who have had stem cell transplant. With new reagent suppliers on board, it says the FDA has now lifted the hold. 

More: FDA eases hold as Marker Therapeutics T-cell manufacturing issues addressed 
Source: fierce